| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
143,520,000 |
| Market
Cap: |
63.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4425 - $0.4425 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapeutics for patients with eye disorders. Co.'s primary product candidate, EYP-19, is a potential sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration. YUTIQ 50 (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is for the treatment of non-infectious uveitis affecting the posterior segment of the eye. DEXYCU® (dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
23,240 |
1,455,005 |
4,817,297 |
4,817,297 |
| Total Buy Value |
$184,500 |
$20,755,667 |
$89,680,913 |
$89,680,913 |
| Total People Bought |
4 |
5 |
5 |
5 |
| Total Buy Transactions |
4 |
6 |
10 |
10 |
| Total Shares Sold |
11,625 |
34,875 |
6,196,374 |
6,756,904 |
| Total Sell Value |
$116,995 |
$383,745 |
$121,650,158 |
$128,737,345 |
| Total People Sold |
1 |
1 |
7 |
8 |
| Total Sell Transactions |
1 |
3 |
27 |
35 |
| End Date |
2024-06-20 |
2024-03-19 |
2023-09-19 |
2022-09-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2024-01-24 |
4 |
S |
$25.01 |
$281,415 |
D/D |
(11,251) |
36,505 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2024-01-24 |
4 |
OE |
$12.90 |
$146,426 |
D/D |
11,251 |
47,756 |
|
- |
|
| Lurker Nancy |
Executive Vice Chair |
• • – |
2024-01-23 |
4 |
S |
$24.97 |
$125,950 |
D/D |
(5,044) |
165,397 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2024-01-23 |
4 |
S |
$25.00 |
$128,375 |
D/D |
(5,135) |
36,505 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2024-01-23 |
4 |
OE |
$12.90 |
$66,954 |
D/D |
5,135 |
41,640 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2024-01-23 |
4 |
S |
$25.00 |
$22,500 |
D/D |
(900) |
37,962 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2024-01-23 |
4 |
OE |
$3.26 |
$6,790 |
D/D |
900 |
38,862 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2024-01-22 |
4 |
S |
$22.24 |
$772,691 |
D/D |
(34,166) |
37,962 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2024-01-22 |
4 |
OE |
$10.13 |
$353,359 |
D/D |
34,166 |
72,128 |
|
- |
|
| Ocumension Therapeutics |
Director |
– • – |
2024-01-11 |
4 |
S |
$19.45 |
$37,159,225 |
D/D |
(1,910,500) |
100,221 |
|
- |
|
| Liu Ye |
|
– • – |
2024-01-11 |
4 |
S |
$19.45 |
$37,159,225 |
I/I |
(1,910,500) |
100,221 |
|
- |
|
| Cormorant Global Healthcare Master Fund, Lp |
|
• • • |
2024-01-11 |
4 |
B |
$19.75 |
$14,812,500 |
I/I |
750,000 |
6,893,235 |
0.01 |
- |
|
| Cormorant Global Healthcare Master Fund, Lp |
|
• • • |
2024-01-09 |
4 |
B |
$21.32 |
$2,238,600 |
I/I |
105,000 |
6,143,235 |
0.01 |
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2024-01-08 |
4 |
S |
$21.13 |
$484,124 |
D/D |
(22,913) |
36,505 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2024-01-08 |
4 |
OE |
$3.26 |
$74,696 |
D/D |
22,913 |
59,418 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2024-01-06 |
4 |
D |
$20.40 |
$84,599 |
D/D |
(4,147) |
37,962 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2024-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,285 |
42,109 |
|
- |
|
| Duker Jay S. |
President and CEO |
• • – |
2024-01-06 |
4 |
D |
$20.40 |
$133,171 |
D/D |
(6,528) |
43,486 |
|
- |
|
| Duker Jay S. |
President and CEO |
• • – |
2024-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,793 |
50,014 |
|
- |
|
| Lurker Nancy |
Executive Vice Chair |
• • – |
2024-01-06 |
4 |
D |
$20.40 |
$470,077 |
D/D |
(23,043) |
170,441 |
|
- |
|
| Lurker Nancy |
Executive Vice Chair |
• • – |
2024-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
75,133 |
193,484 |
|
- |
|
| Elston George |
Chief Financial Officer |
• – – |
2024-01-06 |
4 |
D |
$20.40 |
$100,184 |
D/D |
(4,911) |
35,308 |
|
- |
|
| Elston George |
Chief Financial Officer |
• – – |
2024-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,285 |
40,219 |
|
- |
|
| Pine Michael Craig |
Chief Corp Dev.&Strat. Officer |
• – – |
2024-01-06 |
4 |
D |
$20.40 |
$121,706 |
D/D |
(5,966) |
13,662 |
|
- |
|
| Pine Michael Craig |
Chief Corp Dev.&Strat. Officer |
• – – |
2024-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,285 |
19,628 |
|
- |
|
284 Records found
|
|
Page 3 of 12 |
|
|
